Physician profile
Sung S Lim
NPI 1366558744
$124,926.33
in general payments reported to CMS, 2019-2025
16 companies · $20K in 2025
The $20K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $7,410 · 2021: $27K · 2022: $22K · 2023: $22K · 2024: $26K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Travel and Lodging: $3,493 · Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,636.48 |
| Travel and Lodging | $3,492.50 |
| Food and Beverage | $1,807.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $31,550.26 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $27,494.15 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $11,738.34 | 2020-2024 | |
| Ucb, INC. | $11,655.00 | 2020-2023 | |
| Ucb Sa | $11,525.00 | 2020-2025 | |
| Pfizer INC. | $10,000.00 | 2021-2022 | |
| Astrazeneca Uk Limited | $7,383.75 | 2022-2025 | Saphnelo |
| F. Hoffmann-La Roche Ag | $4,981.48 | 2025 | |
| Biogen, INC. | $4,004.12 | 2021-2023 | |
| Ucb Gmbh | $2,012.50 | 2021 | |
| Janssen Research & Development, LLC | $1,860.00 | 2022 | |
| Genentech, INC. | $575.00 | 2025 | Gazyva |
| Genentech USA, INC. | $146.73 | 2025 | Gazyva |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sung Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.